Lupus
REGISTRATION CLOSED
Systemic lupus erythematosus is a disease that affects women to a greater extent, with a ratio of 9 women to every man1. It is a disease that is difficult to identify because its symptoms are intermittent, vary according to the patient and are often confused with other diseases2 . Find out more about Systemic Lupus Erythematosus (SLE) in our Patient Portal.
Average diagnosis time
In Spain, the average time from the onset of symptoms to diagnosis is 2 years according to the RELESSER 3 registry.
Early detection of activity
The first 5 years after diagnosis are crucial to avoid irreversible organ damage5.
"Ellas – Lupus Call"
29 proposals to anticipate damage and transform the
way we understand and treat
autoimmune diseases.
Because arriving early makes a difference.
Challenges
Challenges
Lupus poses key challenges in several areas
We are promoting the Lupus (SLE) Challenge to foster the search for innovative projects that achieve early identification of disease activity and help prevent the onset of irreversible organ damage, a serious consequence that limits patients' quality of life.
Challenge
How can we optimize the clinical management of patients with systemic lupus erythematosus for early identification and thus prevent irreversible organ damage?
Your solution could be the answer
If you have a startup or innovative project, sign up to apply your solution to improve the quality of life of lupus patients and access GSK benefits.
PARTICIPANTS
Who can participate?
Startups, research centers, universities, spin-offs, and any entity or organization, national or international, that is the exclusive owner of innovative technologies with the potential to solve challenges.
Take on the challenge and solve one or more of the proposed use cases.
They are considered medical devices and have the CE and MDR marking within the regulatory framework.
They must be protected or in the process of obtaining intellectual property rights. They must be transferable or licensable.
Have high growth potential and scalability.
*Includes having at least a TRL 6 (system or subsystem model or prototype demonstration in a relevant environment)
Cómo participar
Candidate Kit
Please read the candidate kit carefully and review the registration form.
Prepare the information
Complete the registration form and verify all information.
Registration form
The call is currently closed.
Find out what we offer
Growth
Explore new opportunities with the opportunity to develop your solution. GSK will work with you as a catalyst for your access to the healthcare system through seed financing.
Learning
Receive guidance and support on aspects related to research, development, and strategy within the healthcare sector. We'll also provide our expertise in regulatory, legal, and operational matters.
Connection
We facilitate access to healthcare professionals, patients, companies, and other organizations that share your solution's purpose. Collaborate with relevant industry players to solve the challenge together.
References
1. Lupus Foundation of America. Lupus Facts and Statistics [Internet]. U.S.: National Resource Center on Lupus; 2022. [Accessed February 2025]. Available from: https://www.lupus.org/es/resources/datos-y-estadisticas-sobre-el-lupus 2. Mayo Clinic . Lupus [Internet]. Spain ; 2022.
[Accessed February 2025]. Available from : https://www.mayoclinic.org/es/diseases-conditions/lupus/diagnosis-treatment/drc-20365790
3. Rúa-Figueroa I, et al. National registry of patients with systemic lupus erythematosus of the Spanish Society of Rheumatology: objectives and methodology. Rheumatol Clin. 2014 Jan-Feb;10(1):17-24. doi: 10.1016/j.reuma.2013.04.013
4. Fanouriakis A, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024 Jan 2;83(1):15-29. doi: 10.1136/ard-2023-224762
5. Rúa-Figueroa I, et al Preventing organ damage in systemic lupus erythematosus: the impact of early biological treatment. Expert Opinion Biol Ther. 2022 Jul;22(7):821-829. doi: 10.1080/14712598.2022.2096406.